Previous 10 | Next 10 |
Experienced Medical Device and Reimbursement Executives Added to Board Ahead of Key Product Milestones and Pre-FDA Meetings IRVINE, CA / ACCESSWIRE / September 16, 2019 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI)(NASDAQ:HJLIW), a developer of medical devices that restore car...
Presentation Featured VenoValve as Potential Treatment of Chronic Venous Disease IRVINE, CA / ACCESSWIRE / August 29, 2019 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI, HJLIW), a developer of medical devices that restore cardiac and vascular health, announced today that on August 25,...
IRVINE, CA / ACCESSWIRE / August 27, 2019 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI) (NASDAQ:HJLIW), a developer of medical devices that restore cardiac and vascular health, has been invited to present at the H.C. Wainwright 21 st Annual Global Investment Conference on September ...
Eight Patients Now Part of First-in-Man Bogota Study IRVINE, CA / ACCESSWIRE / August 20, 2019 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI, HJLIW), a developer of medical devices that restore cardiac and vascular health, has successfully implanted VenoValves in two additional patien...
Reflux Now at Normal Levels in All Four VenoValve Patients IRVINE, CA / ACCESSWIRE / July 26, 2019 / Hancock Jaffe Laboratories, Inc. (Nasdaq: HJLI, HJLIW), a developer of medical devices that restore cardiac and vascular health, announced today that on Thu...
Management to Host VenoValve Webcast and Conference Call on July 25, 2019 at 11:00 am Eastern Time IRVINE, CA / ACCESSWIRE / July 19, 2019 / Hancock Jaffe Laboratories, Inc. (Nasdaq: HJLI, HJLIW), a developer of medical devices that restore cardiac and vascular hea...
No Device Failures in Eight Test Subjects IRVINE, CA / ACCESSWIRE / June 27, 2019 / Hancock Jaffe Laboratories, Inc. (NASDAQ: HJLI, HJLIW), a developer of medical devices that restore cardiac and vascular health, today provided an update on the status of its CoreoGraft animal feasibi...
Clinical Manifestations of CVI Improved an Average of 46% Across All Five VenoValve Patients IRVINE, CA / ACCESSWIRE / June 24, 2019 / Hancock Jaffe Laboratories, Inc. (NASDAQ: HJLI, HJLIW), a developer of medical devices that restore cardiac and vascular health, announced today that on...
IRVINE, CA / ACCESSWIRE / June 20, 2019 / Hancock Jaffe Laboratories, Inc. (NASDAQ: HJLI, HJLIW), a developer of medical devices that restore cardiac and vascular health, today announced that Brian Roselauf will be joining the company as its Director of Research and Development. Mr. Rosela...
VenoValve Presentation on June 23, 2019 in Orlando, Florida IRVINE, CA / ACCESSWIRE / June 19, 2019 / Hancock Jaffe Laboratories, Inc. (NASDAQ: HJLI, HJLIW), a developer of medical devices that restore cardiac and vascular health, announced today that Dr. Jorge Hernando Ulloa, HJLI's ...
News, Short Squeeze, Breakout and More Instantly...
Hancock Jaffe Laboratories Inc. Company Name:
HJLI Stock Symbol:
NASDAQ Market:
Company Now Trading Under Ticker Symbol "NVNO" IRVINE, CA / ACCESSWIRE / October 1, 2021 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, announced today that it has successfully comple...
Live webinar followed by Q&A on Monday, September 27 th at 1:00 PM ET with Robert Berman Chief Executive Officer of Hancock Jaffe Laboratories IRVINE, CA / ACCESSWIRE / September 24, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI) ("Hancock Jaffe" or the "Company"), a medic...
- Hancock Jaffe changing name to enVVeno Medical Corporation and ticker symbol to NASDAQ: NVNO, effective October 1, 2021 - - Development strategy to focus on venous disease and advancement of the VenoValve® - - Initiated development of second product for the treatment of veno...